Johnson & Johnson Stock Valuation Puzzle: Undervalued or Overpriced?
Johnson & Johnson's stock has had a remarkable run over the past three years, delivering an impressive total return of 80.4%. However, its latest valuation checks paint a mixed picture. On one hand, the Discounted Cash Flow (DCF) model suggests that the stock is undervalued, with an estimated intrinsic value of around $364 per share, which is about 27% below its current price.
The DCF model takes into account the company's projected free cash flows and assumes they will continue to grow. This approach points to upside potential in Johnson & Johnson's stock. In contrast, market-based multiples such as the P/E ratio indicate that the shares are not cheap, with a P/E of around 30.5x.
Johnson & Johnson is trading at a premium compared to its peers in the pharmaceutical industry. This could be due to its established portfolio and scale. However, it also means investors are paying more for each dollar of current earnings than the sector average.